Table 3.
Summary of Findings
| Review question | What are the CMR predictors for clinical worsening and mortality in patients with PAH? | ||
| Population | 1,938 participants, including 68% female subjects, aged 52 ± 15 yrs. Participants had more advanced disease and intermediate to high risk for 1-yr mortality |
||
| Follow-up | 22 ± 4 months for clinical worsening and 54 ± 5 months for mortality | ||
| Setting | Tertiary pulmonary hypertension referral centers | ||
| Studies | Case series and case-control studies | ||
| Quality of evidence | Some concerns for bias due to small sample sizes, retrospective design, lack of blinding in most studies and non-consecutive inclusion in half of the studies. | ||
| Results | Increment | Clinical Worsening (Over 22 Months) | Mortality Risk (Over 54 Months) |
| RVEF | per 1% decrease | 4.9% increase | 2.1% increase |
| RVESVI | per 1 ml/m2 increase | 1.3% increase | 0.9% increase |
| RVEDVI | per 1 ml/m2 increase | 1% increase | 0.6% increase |
| LVEDVI | per 1 ml/m2 decrease | Not significant | 1.8% increase |
| LVSVI | per 1 ml/m2 decrease | Not significant | 2.5% increase |